GMP Cleanroom Consultancy UK

GMP Cleanroom Consultancy Expertise

Our consultancy focuses on sterile facility design review, contamination control strategy integration and validation lifecycle planning within GMP-regulated environments.

With experience spanning NHS aseptic preparation units, commercial sterile manufacture and facility refurbishment programmes, we support cleanroom projects from early concept through to qualification and operational readiness.

We translate Annex 1 (2023) and Annex 15 lifecycle validation requirements into practical, inspection-ready facility and governance frameworks. We assess material and personnel flows, airlock strategy, pressure cascade design, cleanability and contamination pathways to ensure full regulatory alignment.

Engagements are structured to provide inspection-defensible outputs suitable for review and approval within client quality systems.

Typical areas of focus include:

• Annex 1 (2023) aligned facility and cleanroom layout review

• URS development and Design Qualification (DQ) readiness support

• Contamination Control Strategy (CCS) development and integration

• Lifecycle validation strategy (DQ, IQ, OQ, PQ) aligned to Annex 15

• NHS aseptic and radiopharmacy project support

Regulatory Framework and Inspection Alignment

Our consultancy is grounded in EU GMP EudraLex Volume 4 and aligned to Annex 1 (2023) requirements for sterile manufacture. We support clients in translating regulatory expectations into practical, inspection-defensible facility and quality system controls.

We provide structured support aligned to Annex 15 lifecycle validation principles, ensuring Design Qualification, Installation Qualification, Operational Qualification and Performance Qualification activities are integrated from early concept through operational readiness.

Where required, we support organisations preparing for MHRA inspection, GMP re-inspection or significant facility variation, with particular focus on Contamination Control Strategy (CCS) integration and documented governance frameworks.

Our Structured Approach

Each engagement follows a defined methodology to ensure clarity, traceability and regulatory alignment. We begin with structured design review and risk identification, followed by URS development, DQ readiness assessment and contamination control strategy integration. Validation lifecycle planning is embedded early to avoid reactive remediation and ensure documentation outputs are suitable for review within regulated pharmaceutical quality systems.